2. Academic Validation
  3. Severe Asthma and Biological Therapies: Now and the Future

Severe Asthma and Biological Therapies: Now and the Future

  • J Clin Med. 2023 Sep 8;12(18):5846. doi: 10.3390/jcm12185846.
Olaia Sardon-Prado 1 2,  Carolina Diaz-Garcia 3,  Paula Corcuera-Elosegui 1,  Javier Korta-Murua 1,  Jose Valverde-Molina 4 5,  Manuel Sanchez-Solis 5 6 7
Affiliations

Affiliations

  • 1 Division of Paediatric Respiratory Medicine, Donostia University Hospital, 20014 San Sebastián, Spain.
  • 2 Department of Pediatrics, University of the Basque Country (UPV/EHU), 20014 Leioa, Spain.
  • 3 Paediatric Pulmonology and Allergy Unit, Santa Lucia General University Hospital, 30202 Cartagena, Spain.
  • 4 Department of Paediatrics, Santa Lucía General University Hospital, 30202 Cartagena, Spain.
  • 5 IMIB Biomedical Research Institute, 20120 Murcia, Spain.
  • 6 Department of Pediatrics, University of Murcia, 20120 Murcia, Spain.
  • 7 Paediatric Allergy and Pulmonology Units, Virgen de la Arrixaca University Children's Hospital, 20120 Murcia, Spain.
PMID: 37762787 DOI: 10.3390/jcm12185846
Abstract

Recognition of phenotypic variability in pediatric asthma allows for a more personalized therapeutic approach. Knowledge of the underlying pathophysiological and molecular mechanisms (endotypes) of corresponding biomarkers and new treatments enables this strategy to progress. Biologic therapies for children with severe asthma are becoming more relevant in this sense. The T2 phenotype is the most prevalent in childhood and adolescence, and non-T2 phenotypes are usually rare. This document aims to review the mechanism of action, efficacy, and potential predictive and monitoring biomarkers of biological drugs, focusing on the pediatric population. The drugs currently available are omalizumab, mepolizumab, benralizumab, dupilumab, and 1ezepelumab, with some differences in administrative approval prescription criteria between the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Previously, we described the characteristics of severe asthma in children and its diagnostic and therapeutic management.

Keywords

1ezepelumab; benralizumab; biologic; biomarkers; dupilumab; mepolizumab; omalizumab; phenotype; severe asthma.

Figures
Products